[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-mitral-regurgitation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-mitral-regurgitation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,69,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100610682","coronary-heart-disease-complicated-with-ischemic-mitral-regurgitation-in-china-100610682",false,"NCT07230756","Coronary Heart Disease Complicated With Ischemic Mitral Regurgitation in China","A Prospective Cohort Study of Coronary Heart Disease Complicated With Ischemic Mitral Regurgitation in China","China-IMR","Inclusion Criteria:\n\n* Age ≥18 years, secondary mitral regurgitation discovered during outpatient visit or hospitalization;\n* Have definite coronary heart disease\n* Cardiac ultrasound: consistent with mitral regurgitation caused by myocardial ischemia or myocardial infarction:\n\n  1. Segmental wall motion abnormality or\n  2. Mitral regurgitation is consistent with Carpentier type IIIb (eccentric regurgitation)\n* Cardiac ultrasound prompts: moderate or above ischemic mitral regurgitation\n\nExclusion Criteria:\n\n* Patients within the past year or currently participating in other clinical studies;\n* Primary mitral regurgitation (such as mitral valve prolapse, perforation, chordae tendineae rupture, etc.);\n* Dilated cardiomyopathy, hypertrophic cardiomyopathy and other diseases;\n* Moderate and above aortic stenosis\u002Fregurgitation, mitral stenosis, tricuspid stenosis, etc.;\n* Patients who have undergone cardiac valve intervention\u002Fsurgery.","ALL","18 Years",{"count":20,"type":21},6000,"ESTIMATED","2 Years","OBSERVATIONAL","This project will rely on the established multi-center cooperation platform for total valve disease and based on the Carpentier classification, which is newly proposed and widely recognized by the academic community, and will specifically target the population with coronary heart disease combined with Ischemic Mitral Regurgitation（IMR） to conduct a nationwide, multi-center, single valve disease, prospective cohort. Research. From November 2025 to December 2025, 6,000 patients with coronary heart disease combined with moderate or above IMR were consecutively selected from outpatients or inpatients in 21 regional medical centers across the country, and clinical characteristics, imaging data, and serology were collected. Information, drug\u002Fsurgical intervention status and clinical outcome indicators were included in the clinical follow-up at baseline, 3 months, 6 months, 12 months and 24 months respectively. The main research objectives are to describe the disease characteristics, treatment status and clinical outcomes of coronary heart disease patients with IMR; to evaluate the current application status of GDMT strategies in IMR diagnosis and treatment practice and its impact on mid- and long-term prognosis. The secondary research objectives are to identify factors affecting prognosis, construct a risk stratification model for mid- and long-term prognosis, and discover new molecular markers.\n\nThis project will for the first time construct the world's largest clearly defined cohort of coronary heart disease combined with IMR. Its research results can provide high-quality data and decision-making basis for precise diagnosis and treatment of IMR populations. Therefore, this project has important scientific research value and clinical guidance significance.",[26,27],"Ischemic Mitral Regurgitation","Coronary Heart Disease (CHD)","NOT_YET_RECRUITING","2025-11-14",{"date":31,"type":32},"2025-11-17","ACTUAL",{"date":34,"type":21},"2025-11-10",{"date":36,"type":21},"2029-12-31",{"name":38,"class":39},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100586614","phase-4-treatment-of-moderate-ischemic-mitral-regurgitation-in-patients-with-coronary-artery-disease-100586614","NCT06917664","Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease","Inclusion Criteria:\n\n1. Fully informed and voluntarily signed informed consent;\n2. Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC\u002FEACTS Guidance Standards )\n\nExclusion Criteria:\n\n1.Symptomatic hypotension and\u002For a SBP \\\u003C 100 mmHg at screening; 2.Estimated GFR \\\u003C 30 mL\u002Fmin\u002F1.73m2; 3.Serum potassium \\> 5 mmol\u002FL at screening; 4.History of angioedema or unacceptable side effects while receiving ACE inhibitors or ARBs; 5.Patients receiving mitral valve intervention at the same time, or have participated in other clinical trials, or are unwilling to participate in this study.",{"count":47,"type":21},220,"INTERVENTIONAL",[50],"PHASE4","This study aims to evaluate the effect of angiotensin receptor\u002Fneprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.",[53,26,54],"Coronary Artery Disease","Angiotensin Receptor\u002FNeprilysin Inhibitor",[56,57,58],"coronary artery disease","ischemic mitral regurgitation","angiotensin receptor\u002Fneprilysin inhibitor","RECRUITING","2025-08-20",{"date":62,"type":32},"2025-08-27",{"date":64,"type":32},"2025-06-05",{"date":66,"type":21},"2027-06",{"name":38,"class":39},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":48,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":68},"100475302","phase-2-serotonin-receptor-blockers-in-ischemic-mitral-regurgitation-100475302","NCT05469165","Serotonin Receptor Blockers in Ischemic Mitral Regurgitation","Blocking the Effects of Serotonin to Prevent Ischemic Mitral Regurgitation: a Randomized Trial (CYPRO-MR)","CYPRO-MR","Inclusion Criteria:\n\n1. Patients 18-80 years old with a 1st episode of STEMI with documented coronary obstruction.\n2. Left ventricle ejection fraction (LVEF)\\\u003C50% and mitral tenting area ≥ 4 cm2, OR LVEF ≤ 40% and inferior\u002Fposterior wall motion anomaly, OR LVEF≤30% and wall motion in any territory.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Hemodynamic instability \u002F cardiogenic shock \u002F papillary muscle rupture\n3. Prior mitral valve procedure\u002Fsurgery\n4. Permanent atrial fibrillation (limiting imaging and MR quantification)\n5. Primary mitral disease (endocarditis, rheumatic, degenerative or congenital)\n6. More than mild valvular disease (other than mitral) at baseline\n7. Planned cardiac surgery (CABG or valve intervention) within 3 months\n8. Contraindications for MRI\n9. Ongoing treatment with selective serotonin reuptake inhibitor (SSRI)\n10. Chronic use of sedative medication\n11. Ongoing or planned pregnancy\n12. Chronic renal failure with Estimated Glomerular Filtration Rate (eGFR) \\\u003C 30 mL\u002Fmin\n13. Neurocognitive disorder\n14. Symptom or prior episode of urinary obstruction or glaucoma (relative contraindications for cyproheptadine)","80 Years",{"count":79,"type":21},214,[81],"PHASE2","This study is intended to investigate the effect of cyproheptadine (a 5HT2B receptor blocker) on mitral regurgitation severity.",[26],[85,86,87,88,89],"Ischemic mitral regurgitation","Myocardial infarction","Mitral valve","Serotonin","Cyproheptadine","2023-11-13",{"date":92,"type":32},"2023-11-15",{"date":94,"type":32},"2023-06-20",{"date":96,"type":21},"2027-09",{"name":98,"class":99},"Laval University","OTHER",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":48,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":68},"100392927","epicardial-mitral-touch-system-for-mitral-insufficiency-100392927","NCT04396379","Epicardial Mitral Touch System for Mitral Insufficiency","ENRAPTUS Epicardial Mitral Touch System for Mitral Insufficiency","ENRAPTUS","Inclusion Criteria:\n\n* Moderate or greater (2+) ischemic\n* Functional Mitral regurgitation by 2D echocardiography using an integrative method\n* Patient is scheduled for cardiac surgery (e.g. CABG including patients on the waiting list for Heart Transplantation)\n* Patient is 22 years of age or older\n* Patient is willing and able to sign Informed Consent Form\n* Within 90 days patients should be on stable optimally uptitrated medical therapy recommended according to current guidelines23 as standard of care for heart failure therapy in the United States\n\nExclusion Criteria:\n\n* Any evidence of structural (chordal or leaflet) mitral valve disease\n* Inability to derive ERO, LVESVI or LVEDVI by TTE\n* Prior surgical or percutaneous mitral valve intervention\n* Contraindication to cardiopulmonary bypass (CPB)\n* Clinical signs of cardiogenic shock\n* Treatment with chronic intravenous inotropic therapy\n* Severe, irreversible pulmonary hypertension in the judgement of the investigator\n* ST segment elevation requiring intervention within 7 days prior to randomization\n* Congenital heart disease (except PFO or ASD)\n* Evidence of cirrhosis or hepatic synthetic failure\n* Renal insufficiency (eGFR \\\u003C 30 ml\u002Fmin)\n* History of endocarditis or current endocarditis\n* Ejection fraction \\\u003C25%\n* NY heart class IV\n* MV diameters \\> 7cm\n* Any coronary artery calcification at site of placement as determined by angiogram\n* Myxomatous mitral regurgitation\n* Women who are pregnant (by history of menstrual period or pregnancy test if history is considered unreliable)\n* Abnormal cardiac anatomy discovered prior to surgery or during procedure\n* Pericardial adhesions\n* Insufficient clinical signature reduction of mitral regurgitation during device sizing and placement. (No device remains, patient moved to only 30-Day follow-up.)","22 Years",{"count":110,"type":21},10,[112],"NA","To evaluate the safety and performance of the Mitral Touch System to treat mitral insufficiency in patients who are to undergo cardiac surgery with either a sternotomy or thoracotomy who present with moderate to severe ischemic or functional mitral regurgitation.",[26,115],"Functional Mitral Regurgitation","2023-01-02",{"date":118,"type":32},"2023-01-04",{"date":120,"type":21},"2023-09-10",{"date":122,"type":21},"2027-12-31",{"name":124,"class":125},"Mitre Medical Corp.","INDUSTRY"]